Genetron Health to Highlight Data from 18 Studies at ESMO 2020
Genetron Health to present data at ESMO 2020 relating to precision oncology diagnostic development initiatives across lung, gastrointestinal and other cancer types, and to bioinformatics development
BEIJING, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening and companion diagnostics development, and its collaborators will present data from 18 studies at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress 2020 taking place on September 19-21.
The abstracts include 15 studies on translational medicine covering various cancer types and three studies on bioinformatics development. Data that will be highlighted at the ESMO Virtual Congress were generated in collaboration with more than 10 notable cancer centers and clinical hospitals in China. In summary, the abstracts are grouped by four topics as follows:
Chinese population’s genetic characteristics:
“We are pleased to showcase our data from 18 research studies at the upcoming ESMO Virtual Congress. These data reflect Genetron Health’s broad research focus and capabilities in various cancer types including lung, gastrointestinal, brain, upper tract urinary and others. Additionally, we have advanced our research in understanding certain genomic characteristics of the Chinese population, target selections and validations, as well as further optimization of our bioinformatics,” remarked Hai Yan, PhD, the Company’s Co-founder and Chief Scientific Officer. “Lung cancer is one of our key focus areas and both the EGFR fusion and RET rearrangement studies could help us further in designing panels to guide clinical treatments. In regards to research studies in gastrointestinal cancer, KMT2C/D mutation findings could potentially be beneficial in identifying colorectal cancer patients for immune checkpoint inhibitor therapies, and gastric cancer patients for other immunotherapies. Furthermore, our research has shown that liquid biopsy plus genetic and epigenetic profiling could help predict the risk of upper tract urinary carcinoma.”
The 18 abstracts include:
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.
Safe Harbor Statement
Investor Relations Contacts
Media Relations Contact
How to Strategically Leverage New Connectivity Options
All Conference Party